Balaji Veeraraghavan
Overview
Explore the profile of Balaji Veeraraghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
295
Citations
2611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roy S, Majumdar A, Nandy S, Pal J, Veeraraghavan B, Walia K, et al.
Infect Genet Evol
. 2025 Mar;
:105736.
PMID: 40057151
Non-typhoidal Salmonella (NTS) infections are a major public health concern in India because of inadequate knowledge of antimicrobial resistance, limiting therapeutic options. The study aimed to characterize and analyse the...
2.
Veeraraghavan B, Shin E, Bakthavatchalam Y, Manesh A, Dubey D, Tascini C, et al.
Antimicrob Agents Chemother
. 2025 Mar;
:e0162724.
PMID: 40035550
In the ATTACK Phase 3 trial examining the efficacy of sulbactam (SUL)/durlobactam (DUR) to treat primarily complex (ABC) infections, imipenem (IPM)/cilastatin was added as a common therapy to both the...
3.
Abraham D, Kathiresan L, Sasikumar M, Aiemjoy K, Charles R, Kumar D, et al.
PLoS Negl Trop Dis
. 2025 Mar;
19(3):e0012373.
PMID: 40029872
Background: Blood culture-based surveillance for typhoid fever has limited sensitivity, and operational challenges are encountered in resource-limited settings. Environmental surveillance targeting Salmonella Typhi (S. Typhi) shed in wastewater (WW), coupled...
4.
Bandyopadhyay R, Mathew S, Veeraraghavan B, Samuel P, Backiyaraj J, Sathyendra S, et al.
JAC Antimicrob Resist
. 2025 Feb;
7(1):dlaf015.
PMID: 39973907
Background: Azithromycin is the only oral option available for XDR enteric fever. Studies correlating azithromycin levels with treatment success are rare. Methods: Serum azithromycin levels after administration of a once-daily...
5.
Veeraraghavan B, Walia K, Egli A
Clin Microbiol Infect
. 2024 Dec;
PMID: 39706363
No abstract available.
6.
Veeraraghavan B, Walia K, Egli A
Clin Microbiol Infect
. 2024 Dec;
PMID: 39672465
No abstract available.
7.
Karthik M, Kacha S, Rajendran S, Bakthavatchalam Y, Lal B, Walia K, et al.
Infect Genet Evol
. 2024 Dec;
126:105701.
PMID: 39653106
Pseudomonas aeruginosa exhibits significant antibiotic resistance facilitated by both intrinsic and acquired mechanisms, prominently through Pseudomonas-derived cephalosporinase (PDC), serine Ambler class C β-lactamases encoded by the AmpC. AmpC, involved in...
8.
Bakthavatchalam Y, Behera B, Shah A, Mathur P, Ray R, Fomda B, et al.
Microbiol Spectr
. 2024 Nov;
13(1):e0049724.
PMID: 39560385
Importance: Metallo-β-lactamases are therapeutically challenging due to the limited treatment options. Against such isolates, currently approved newer β-lactam/β-lactamase inhibitor combinations are ineffective. In this study, we tested siderophore cephalosporin, cefiderocol,...
9.
Bakthavatchalam Y, Karthik R, Ashok A, Walia K, Ragothaman H, Krishnamoorthy S, et al.
Indian J Med Microbiol
. 2024 Nov;
52:100755.
PMID: 39550069
In the present study, we determine the synergistic activity of ertapenem with cefazolin and flucloxacillin against type A beta-lactamase producing Methicillin susceptible Staphylococcus aureus isolate. In the time kill assay,...
10.
Jacob J, Aravind V, Beresford-Jones B, Lal Y, Shankar C, Yesudoss M, et al.
J Epidemiol Glob Health
. 2024 Nov;
14(4):1668-1677.
PMID: 39531180
Background: Klebsiella pneumoniae is a common opportunistic pathogen in humans, often associated with both virulence and antimicrobial resistance (AMR) phenotypes. K. pneumoniae have a highly plastic genome and can act...